Médicaments hypoglycémiants dans le diabète de type 2 et néphroprotection : un nouvel axe thérapeutique ?
(2020) Médecine des Maladies Métaboliques — Vol. 14, n° 1, p. 77-84 (2020)
Files
2020_Buysschaert_Med_Mal_Metab_77-84_Ab.pdf
Abstract
Open Access - Adobe PDF
- 260.37 KB
2020_Buysschaert_Med_Mal_Metab_77-84.pdf
Restricted Access - Adobe PDF
- 597.07 KB
Details
- Authors
- Abstract
- (en) [Hypoglycemic medications in type 2 diabetes and renal protection: A new therapeutic area?] Diabetic nephropathy is currently the leading cause of chronic end stage renal disease with its clinical consequences. Its prevention implies a multipluridisciplinary management based on a strict control of blood glucose from the onset of diabetes, and blood pressure with a dominant place for ACE-i or sartans. Recent clinical trials have demonstrated that metformin but more importantly new classes of antihyperglycemic agents (DDP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors) had in addition to their antihyperglycemic effect a nephroprotective action on renal function and/or albuminuria. Therefore, according to scientific societies, in the presence of renal failure, SGLT-2 inhibitors and, if contra-indicated, GLP-1 receptor agonists should be a first choice in type 2 diabetes after failure of metformin in the context of an individualized approach.
- Affiliations
Citations
Buysschaert, M., Preumont, V., & Buysschaert, B. (2020). Médicaments hypoglycémiants dans le diabète de type 2 et néphroprotection : un nouvel axe thérapeutique ? Médecine des Maladies Métaboliques, 14(1), 77-84. https://doi.org/10.1016/j.mmm.2019.12.005 (Original work published 2020)